Navigation Links
Xanodyne Announces New President/CEO and Completes $38 Million Equity Financing
Date:6/4/2009

NEWPORT, Ky., June 4 /PRNewswire/ -- Xanodyne Pharmaceuticals, Inc. is pleased to announce that Michael J. Valentino has been named to the position of President and Chief Executive Officer and continues as a member of the Company's Board of Directors. In addition to Mr. Valentino's announcement, Xanodyne completed an equity financing of $38 million led by MPM Capital. Current investors' participation also included; AIG Investments' sponsored funds, Aisling Capital, Blue Chip Venture Company, Essex Woodlands Health Ventures, HealthCare Ventures, LLC, and Union Springs.

Mr. Valentino most recently served as President and CEO, Adams Respiratory Therapeutics (Nasdaq: ARXT) and has over 30 years of experience in the healthcare industry, including a broad range of critical leadership positions at major pharmaceutical companies including Alpharma, Novartis AG, Pharmacia/Upjohn and Warner Lambert. Mr. Valentino successfully transformed Adams into a fully integrated specialty pharmaceutical company. In addition, under his leadership Adams completed its initial public offering in July 2005, which was ranked by The Wall Street Journal as the No. 1 Health Care IPO in 2005. In January 2008, he successfully led the sale of the company to Reckitt Benckiser for $2.3B.

Mr. Valentino said, "I look forward to working closely with the Xanodyne management team to bring two exciting pipeline assets to the US marketplace within the next 12-18 months. Our efforts will be focused on aggressively executing our commercialization plans for Zipsor(TM) (diclofenac potassium - acute pain) and XP12B (tranexamic acid - heavy menstrual bleeding). The closing of our financing demonstrates the continued commitment of our investor group to complete the NDA process and execute the launch plans for these two important new products."

Rolf Classon, Chairman of the Board said, "The Board is excited about the achievement of these important milestones for Xanodyne. Mike brings major pharmaceutical and commercial experience to the team while the financing brings the critical resources needed for the launches. Xanodyne is now in a position to expand its current commercial product portfolio with an emerging pipeline to generate near term growth."

About Xanodyne

Xanodyne Pharmaceuticals, Inc., which commenced operations in 2001, is an integrated specialty pharmaceutical company with both development and commercial capabilities focused on women's healthcare and pain management. Xanodyne markets a portfolio of revenue generating products consisting of FDA approved pharmaceuticals and a line of prenatal vitamins. Additionally, Xanodyne is advancing a late stage pipeline of product candidates targeted at significant potential markets in Xanodyne's focus areas.


'/>"/>
SOURCE Xanodyne Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Xanodynes New Drug Application for the Treatment of Heavy Menstrual Bleeding (Menorrhagia) Accepted for Filing with a Priority Review Classification
2. US Oncology, Inc. Announces $465 Million Senior Secured Notes Offering
3. DATATRAK Announces Receipt of NASDAQ Panel Decision to Delist Common Shares
4. CorVel Announces Revenues and Earnings
5. Conceptual Options, a Center for Surrogacy & Egg Donation, Announces Third Party Assurance Program
6. Orlando Dermatology Aesthetic & Clinical (ODAC) Conference Announces Its 2010 Event
7. Synthetech Announces Fiscal 2009 Results
8. Martek Announces Second Quarter 2009 Financial Results
9. Medi-Share Program Announces New Healthcare Program Offerings for Christian Community
10. Ambry Genetics Announces Launch of Chromosomal Microarray to Offer Whole Genome Analysis
11. One Woman Initiative Announces First Grants to Womens Organizations in Five Nations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... , ... June 25, 2016 , ... "With 30 hand-drawn ... specific project," said Christina Austin - CEO of Pixel Film Studios. , ProHand ... all within Final Cut Pro X . Simply select a ProHand generator and ...
(Date:6/25/2016)... Montreal, Canada (PRWEB) , ... June 25, 2016 , ... ... the pursuit of success. In terms of the latter, setting the bar too high ... low, risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... Texas (PRWEB) , ... June 24, 2016 , ... ... International Conference and Scientific Sessions in Dallas that it will receive two significant ... of the grants came as PHA marked its 25th anniversary by recognizing patients, ...
(Date:6/24/2016)... , ... June 24, 2016 , ... People across the ... Genome magazine’s Code Talker Award, an essay contest in which patients and their families ... to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education ...
(Date:6/24/2016)... ... ... National recruitment firm Slone Partners is pleased to announce the ... as Vice President of North American Capital Sales at HTG Molecular . ... team in the commercialization of the HTG EdgeSeq system and associated reagents in North ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016   Bay Area Lyme Foundation ... Dean Center for Tick Borne Illness , Harvard ... MIT Hacking Medicine, University of California, Berkeley, and ... the five finalists of Lyme Innovation , ... than 100 scientists, clinicians, researchers, entrepreneurs, and investors ...
(Date:6/24/2016)... SAN CLEMENTE, Calif. , June 24, 2016  American Respiratory ... testing company, is now able to perform sophisticated lung assessments in ... Medical Technologies , Inc. Patients are no longer ... to ndd,s EasyOne PRO ® , ARL patients like Jeanne R. ... testing done in the comfort of her own home. ...
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, ... less invasive and more durable cerebrospinal fluid treatments, ... funding.  The Series-A funding is led by Innova ... Fund, and other private investors.  Arkis, new financing ... instrumentation and the market release of its in-licensed ...
Breaking Medicine Technology: